Sadowski, C, Belknap, R, Holland, DP, Moro, RN, Chen, MP, Wright, A, Millet, JP, Cayla, JA, Scott, NA, Borisov, A, Gandhi, NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. CLINICAL INFECTIOUS DISEASES. 2023; 76(12)DOI:10.1093/cid/ciad083. PMID:36815322. IF:8.200(Q1/1D).

Cornejo-Sánchez T., Soldevila N., Coronas L., Alsedà M., Godoy P., Razquín E., Sabaté S., Guix S., Rodríguez Garrido V., Bartolomé R., Domínguez A., Álvarez J., Belver A.I., Camps N., Minguell S., Carol M., Izquierdo C., Parrón I., Pérez C., Rovira A., Sabaté M., Sala M.R., Vileu R.M., Barrabeig I., Jané M., Martínez A., Torner N., de Benito J., Moreno-Martínez A., Rius C., de Andres A., Camprubí E., Cunillé M., Forns M.L., de Simón M.. Epidemiology of GII.4 and GII.2 norovirus outbreaks in closed and semi-closed institutions in 2017 and 2018. Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-28448-9. PMID:36717621. IF:3.800(Q1/2D).

Porta M., Pumarega J., Gasull M., Aguilar R., Henríquez-Hernández L.A., Basagaña X., Zumbado M., Villar-García J., Rius C., Mehta S., Vidal M., Jimenez A., Campi L., Lop J., Pérez Luzardo O.L., Dobaño C., Moncunill G.. Individual blood concentrations of persistent organic pollutants and chemical elements, and COVID-19: A prospective cohort study in Barcelona. ENVIRONMENTAL RESEARCH. 2023; 223DOI:10.1016/j.envres.2023.115419. PMID:36740154. IF:7.700(Q1/1D).

Günther G., Guglielmetti L., Leu C., Lange C., van Leth F., Hasan Hafizi, Khachatryan N., Aroyan H., Kabasakalyan E., Knappik M., Skrahina A., Klimuk D., Nikolenka A., Muylle I., Milanov V., Velkovska D., Tarinska N., Bachiyska E., Jankovic M., Pieridou D., Adamide T., Nicolaou N., Vasakova M., Sukholytka M., Kopeckà E., Folkvardsen D.B., Svensson E., Danilovits M., Kummik T., Vasankari T., Fréchet-Jachym M., Nahmiash A., Togonidze T., Avaliani Z., Kinkladze I., Aspindzelashvili R., Bichashvili T., Losaberidze G., Merabishvili T., Kalsdorf B., Manika K., Tsiakitzis K., Bakos A., Ægisdóttir T.R., Michelsen G.S., Karlsdóttir K., McLaughlin A.-M., Fitzgibbon M., Chemtob D., Codecasa L.R., Ferrarese M., Torri S., Gjocaj M., Kuksa L., Davidaviciene E., Wirtz G., Perrin M., Asciak A.P., Chesov D., de Lange W., Akkerman O., Poposka B.I., Mack U., Jensenius M., Kvalvik L., Mengshoel A.T., Kruczak K., Duarte R., Ribeiro N., Ibraim E., Kaluzhenina A., Barkanova O., Pesut D., Solovic I., Svetina P., Souza-Galvão M.-L.D., Millet J.-P., Casas X., Vives M., Bruchfeld J., Dalemo P., Jonsson J., Aeschbacher K., Keller P., Özkara S., Tiberi S., Chen C., Terleeva Y., Dudnyk A.. Availability and costs of medicines for the treatment of tuberculosis in Europe. CLINICAL MICROBIOLOGY AND INFECTION. 2023; 29(1)DOI:10.1016/j.cmi.2022.07.026. PMID:35961488. IF:10.900(Q1/1D).